Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_assertion type Assertion NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_head.
- NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_assertion description "[In conclusion, a 24-month course of treatment with 6 MU IFN-alpha2b was well tolerated by most patients, led to sustained suppression of HBV in one third, and attenuated hepatitis in 81% of patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_provenance.
- NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_assertion evidence source_evidence_literature NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_provenance.
- NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_assertion SIO_000772 9398007 NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_provenance.
- NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_assertion wasDerivedFrom befree-2016 NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_provenance.
- NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_assertion wasGeneratedBy ECO_0000203 NP1385249.RAIwdqj2XwVkoQM-Lv2ZmryKw7b5AOA6OJtUHhNpQvZ5c130_provenance.